A Bayesian approach to the survivor average causal effect in cluster-randomized crossover trials

Abstract: In cluster-randomized crossover (CRXO) trials, groups of individuals are randomly assigned to two or more sequences of alternating treatments. Since clusters act as their own control, the CRXO design is typically more statistically efficient than the usual parallel-arm trial. CRXO trials are increasingly popular in many areas of health research where the number of available clusters is limited. Further, in trials among severely ill patients, researchers often want to assess the effect of treatments on secondary non-terminal outcomes, but frequently in these studies, there are patients who do not survive to have these measurements fully recorded. In this paper, we provide a causal inference framework and treatment effect estimation methods for addressing truncation by death in the setting of CRXO trials. We target the survivor average causal effect (SACE) estimand, a well-defined subgroup treatment effect obtained via principal stratification. We propose novel structural and standard modeling assumptions to enable SACE identification followed by estimation within a Bayesian paradigm. We evaluate the small-sample performance of our proposed Bayesian approach for the estimation of the SACE in CRXO trial settings via simulation studies. We apply our methods to a previously conducted two-period cross-sectional CRXO study examining the impact of proton pump inhibitors compared to histamine-2 receptor blockers on length of hospitalization among adults requiring invasive mechanical ventilation.